Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b (Q79838169)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

9

Krzysztof Selmaj

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

6

David H Miller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Chris Polman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Ludwig Kappos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Mark S Freedman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Gilles Edan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Hans-Peter Hartung

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Xavier Montalbán

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Frederick Barkhof

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Bernard M J Uitdehaag

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Susanne Dahms

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Lars Bauer

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Christoph Pohl

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Rupert Sandbrink

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

BENEFIT investigators

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

15 November 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

number of pages

8

1 reference

inferred from page(s)

published in

Journal of Neurology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

255

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

480-487

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18004635%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-007-0733-2

26 December 2019

exact match

0 references

cites work

The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.

1 reference

12 December 2020

MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

12 December 2020

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

12 December 2020

Is optic neuritis more benign than other first attacks in multiple sclerosis?

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group

1 reference

12 December 2020

Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS.

1 reference

12 December 2020

Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization

1 reference

12 December 2020

Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Predictors of relapse rate in MS clinical trials.

1 reference

12 December 2020

MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study.

1 reference

12 December 2020

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

1 reference

12 December 2020

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

1 reference

12 December 2020

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a

1 reference

12 December 2020